Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET
Company Participants
Wade Walke - Senior Vice President of Investor Relations
Brett Monia - Chief Executive Officer
Richard Geary - Executive Vice President and Chief Development Officer
Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer
Elizabeth Hougen - Executive Vice President and Chief Financial Officer
Eric Swayze - Executive Vice President of Research
Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer
Jonathan Birchall - Chief Commercial Officer
Conference Call Participants
Amy Li - Jefferies
Myles Minter - William Blair
Yanan Zhu - Wells Fargo Securities
Jessica Fye - JPMorgan
Allison Bratzel - Piper Sandler
Yaron Werber - TD Cowen
Jason Gerberry - Bank of America
Jay Olson - Oppenheimer
Michael Ulz - Morgan Stanley
Gary Nachman - Raymond James
Salveen Richter - Goldman Sachs
Kostas Biliouris - BMO Capital Markets
Operator
Good morning, and welcome to the Ionis Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.
Wade Walke
Thank you, Danielle. Before we begin, I encourage everyone to go to the Investors section of the analyst website to view the press release and related financial tables that we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call.
With me on this morning's call are Brett Monia, our Chief Executive Officer; Richard Geary, Chief Development Officer; Kyle Jenne, Chief Global Project Strategy Officer; and Beth Hougen, our Chief Financial Officer; Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Jonathan Birchall, Chief Commercial Officer, will also join us for the Q&A portion of our call.
I'd like to draw your attention to Slide 3 in our presentation, which contains our forward-looking language statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.